Acceleron Pharma (XLRN) Misses Q4 EPS by 36c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acceleron Reports Fourth Quarter and Full Year 2020 Financial Results
February 25, 2021 4:01 PM EST- Updates from ongoing PULSAR and SPECTRA Phase 2 clinical trials of sotatercept in patients with pulmonary arterial hypertension (PAH) presented at the American Heart Association (AHA) 2020 Scientific Sessions -
- STELLAR Phase 3 trial initiated with sotatercept in PAH -
- Acceleron recognized approximately $23.0 million in royalty revenue from approximately $115 million in net sales of REBLOZYL® (luspatercept-aamt) for Q4 2020 and approximately $54.8 million in royalty revenue from approximately $274 million in net sales of REBLOZYL for full year 2020 -
- Multiple clinical presentations on REBLOZYL reviewed... More
